Novo Nordisk (Germany) Technical Analysis
| NOVA Stock | EUR 100.00 0.50 0.50% |
As of the 30th of November, Novo Nordisk secures the Risk Adjusted Performance of (0.14), mean deviation of 1.33, and Standard Deviation of 1.72. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Novo Nordisk AS, as well as the relationship between them. Please verify Novo Nordisk AS mean deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if Novo Nordisk AS is priced some-what accurately, providing market reflects its recent price of 100.0 per share.
Novo Nordisk Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Novo, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to NovoNovo |
Novo Nordisk technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Novo Nordisk AS Technical Analysis
The output start index for this execution was ten with a total number of output elements of fifty-one. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Novo Nordisk AS volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Novo Nordisk AS Trend Analysis
Use this graph to draw trend lines for Novo Nordisk AS. You can use it to identify possible trend reversals for Novo Nordisk as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Novo Nordisk price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.Novo Nordisk Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Novo Nordisk AS applied against its price change over selected period. The best fit line has a slop of 0.37 , which may suggest that Novo Nordisk AS market price will keep on failing further. It has 122 observation points and a regression sum of squares at 5067.45, which is the sum of squared deviations for the predicted Novo Nordisk price change compared to its average price change.About Novo Nordisk Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Novo Nordisk AS on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Novo Nordisk AS based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Novo Nordisk AS price pattern first instead of the macroeconomic environment surrounding Novo Nordisk AS. By analyzing Novo Nordisk's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Novo Nordisk's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Novo Nordisk specific price patterns or momentum indicators. Please read more on our technical analysis page.
Novo Nordisk November 30, 2024 Technical Indicators
Most technical analysis of Novo help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Novo from various momentum indicators to cycle indicators. When you analyze Novo charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (5.82) | |||
| Mean Deviation | 1.33 | |||
| Coefficient Of Variation | (523.35) | |||
| Standard Deviation | 1.72 | |||
| Variance | 2.96 | |||
| Information Ratio | (0.27) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.63) | |||
| Treynor Ratio | (5.83) | |||
| Maximum Drawdown | 9.63 | |||
| Value At Risk | (2.89) | |||
| Potential Upside | 2.39 | |||
| Skewness | (0.09) | |||
| Kurtosis | 0.8463 |
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |